Holen Sie sich die Stockscreener-App
4.23
8.74%
0.34
Handel nachbörslich:
4.23
Schlusskurs vom Vortag:
$3.89
Offen:
$3.89
24-Stunden-Volumen:
191.12K
Relative Volume:
0.62
Marktkapitalisierung:
$39.68M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-1.63%
1M Leistung:
+1.20%
6M Leistung:
-80.64%
1J Leistung:
+0.00%
1-Tages-Spanne:
$3.89
$4.28
1-Wochen-Bereich:
$3.87
$4.4384
52-Wochen-Spanne:
$3.74
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Firmenname
Tvardi Therapeutics Inc
Sektor
Branche
Telefon
(713) 489-8654
Adresse
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Vergleichen Sie TVRD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
4.23 | 36.49M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-14 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-10-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-10-13 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-13 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-14 | Eingeleitet | Raymond James | Outperform |
| 2025-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-12 | Eingeleitet | Piper Sandler | Overweight |
| 2025-05-21 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-15 | Eingeleitet | BTIG Research | Buy |
| 2024-06-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | Herabstufung | Needham | Buy → Hold |
| 2024-06-13 | Herabstufung | Stifel | Buy → Hold |
| 2023-03-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-11-01 | Fortgesetzt | Canaccord Genuity | Buy |
| 2021-08-03 | Eingeleitet | JP Morgan | Neutral |
| 2020-04-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-29 | Bestätigt | Laidlaw | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2019-01-15 | Eingeleitet | BofA/Merrill | Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Eingeleitet | Jefferies | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2018-02-12 | Hochstufung | Janney | Neutral → Buy |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
Alle ansehen
Tvardi Therapeutics Inc Aktie (TVRD) Neueste Nachrichten
Will Tvardi Therapeutics Inc. stock split attract more investorsWeekly Gains Summary & Technical Buy Zone Confirmation - ulpravda.ru
Can Tvardi Therapeutics Inc. stock outperform in 2025 bull market2025 Support & Resistance & Low Volatility Stock Suggestions - ulpravda.ru
Will Tvardi Therapeutics Inc. stock recover faster than peersPortfolio Performance Report & Free Technical Confirmation Trade Alerts - ulpravda.ru
Can Tvardi Therapeutics Inc. (69C) stock stage a strong rebound this quarterWeekly Investment Report & Weekly High Return Forecasts - ulpravda.ru
Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Tvardi Therapeutics TTI-101 shows 9.4% fibrosis score decrease versus 2.4% placebo - MarketScreener
Tvardi reports improved fibrosis scores with TTI-101 in IPF trial - Investing.com Canada
Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights - GlobeNewswire
Why Tvardi Therapeutics Inc stock is seen as undervaluedWeekly Risk Summary & Free Fast Gain Swing Trade Alerts - moha.gov.vn
MSN Money - MSN
Street Watch: Can Tvardi Therapeutics Inc stock outperform in 2025 bull marketWeekly Risk Report & Safe Capital Investment Plans - moha.gov.vn
Tvardi Therapeutics (NASDAQ:TVRD) Upgraded at Wall Street Zen - Defense World
Will Q4 Earnings Be a Catalyst for Cubex Tubings LimitedEconomic Data Impact & Free Hedging Tactics for Volatile Markets - earlytimes.in
Why Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today? - MSN
Tvardi Therapeutics, Inc. (TVRD) Total Expenses (TTM) - Zacks Investment Research
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
What drives Tvardi Therapeutics Inc. (69C) stock priceEarnings Volatility Patterns & Capitalize On Momentum - earlytimes.in
Tvardi Therapeutics (NASDAQ:TVRD) Stock Rating Lowered by Wall Street Zen - Defense World
What drives Tvardi Therapeutics Inc 69C stock priceLarge Cap Stability Picks & Low Cost Stock Ideas - earlytimes.in
INVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics - TMX Newsfile
Pittsburgh Post-GazetteTvardi Therapeutics, Inc.Common Stock (Nasdaq:TVRD) Stock Quote - FinancialContent
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics - FinancialContent
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics - GuruFocus
Tvardi Therapeutics (NASDAQ:TVRD) Rating Increased to Hold at Wall Street Zen - Defense World
Why retail investors favor Tvardi Therapeutics Inc. stockMarket Activity Report & Free High Return Stock Watch Alerts - Улправда
SHAREHOLDER INVESTOR REMINDER: Faruqi & Faruqi, LLP - GlobeNewswire
Can Tvardi Therapeutics Inc. stock sustain market leadershipPortfolio Value Summary & Low Risk High Win Rate Picks - Bölüm Sonu Canavarı
Will Tvardi Therapeutics Inc. stock see insider buyingIPO Watch & Weekly Market Pulse Updates - Улправда
Tvardi Therapeutics grants retention stock options and adopts new severance plan - Investing.com Nigeria
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims o - GuruFocus
Tvardi Therapeutics Earnings Notes - Trefis
What analysts say about Tvardi Therapeutics Inc stockCash Flow Trends & Affordable Portfolio Growth - earlytimes.in
Tvardi Therapeutics Advances STAT3 Inhibitor Clinical Trials - MSN
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics - TMX Newsfile
Tvardi Therapeutics (TVRD) Price Target Decreased by 24.64% to 15.15 - MSN
How Low Can Tvardi Therapeutics Stock Really Go? - Trefis
Tvardi Therapeutics (TVRD) Stock Analysis Report | Financials & Insights - Benzinga
Will Tvardi Therapeutics Inc. (69C) stock outperform value peersJuly 2025 Weekly Recap & Free Daily Entry Point Trade Alerts - Newser
Can Tvardi Therapeutics Inc. stock sustain institutional interestTrade Exit Summary & Detailed Earnings Play Alerts - Newser
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates - GuruFocus
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics - Barchart.com
TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims On Behalf Of Investors Of Tvardi Therapeutics - Menafn.com
Is Tvardi Therapeutics Inc. (69C) stock trading at attractive multiplesChart Signals & Fast Exit and Entry Trade Guides - Newser
Why Tvardi Therapeutics Inc. (69C) stock could outperform next yearWeekly Profit Analysis & Technical Pattern Recognition Alerts - Newser
Finanzdaten der Tvardi Therapeutics Inc-Aktie (TVRD)
Es liegen keine Finanzdaten für Tvardi Therapeutics Inc (TVRD) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
4.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):